ArticleScientific reports2025
Investigation of the mechanism of euphornin against cervical cancer using network pharmacology.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Euphornin has potential therapeutic effect on cervical cancer (CC). To elucidate the mechanism of euphornin in treating CC, the strategy of combining network pharmacology and in vitro cell experiments was adopted. Network pharmacology analysis was conducted to obtain the core targets and key pathways associated with euphornin's therapeutic action against CC. Molecular docking tools were employed to analyze the affinity between euphornin and its core targets. Western blot was applied to verify the core target proteins and the key signaling pathways. Wound healing and transwell assays were performed to assess the migration and invasion of CC cells, and flow cytometry was conducted to evaluate CC cells' rate of apoptosis. Ten core targets of euphornin in treating CC were identified, and enrichment analysis revealed their involvement in apoptosis, miRNA metabolism/transcription/regulation, and p53 pathways. It was demonstrated by molecular docking analysis that there was a high affinity between euphornin and ESR1. Compared to the control group, euphornin significantly inhibited CC cell migration and invasion, accompanied by decreased expression of EGFR, MDM2, MMP-2, and MMP-9 (P < 0.05), along with increased expression of caspase3, ESR1, p-p53 and p53 (P < 0.05). Compared to the pcDNA3.1 group, the transfected pcDNA3.1 with ESR1 exhibited a remarkable increase in ESR1 expression (P < 0.0001), and significant inhibition on CC cell migration and invasion (P < 0.001). In addition, the apoptosis rate of CC cells and the expression of cleaved-caspase3, cleaved-caspase8, and cleaved-caspase9 increased significantly (P < 0.001). Compared to the euphornin + si-NC group, the migration and invasion of Hela cells in the euphornin + si-ESR1 group increased significantly (P < 0.01), while their apoptosis decreased significantly (P < 0.001). Our study identifies targets of euphornin in treating CC and proposes that its mechanism potentially involves the regulation of the MDM2-p53 signaling pathway. ESR1 was revealed to be a potential anti-CC target of euphornin, and euphornin was demonstrated to inhibit CC cell migration and invasion, and promote CC cell apoptosis by targeting ESR1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.